Haleon plc (HLNCF)
| Market Cap | 44.08B |
| Revenue (ttm) | 14.23B |
| Net Income (ttm) | 1.38B |
| Shares Out | n/a |
| EPS (ttm) | 0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.03 (0.52%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 300 |
| Open | 4.950 |
| Previous Close | n/a |
| Day's Range | 4.748 - 4.950 |
| 52-Week Range | 3.810 - 5.360 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 5, 2025 |
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops,... [Read more]
Full Company ProfileFinancial Performance
In 2023, Haleon's revenue was 11.30 billion, an increase of 4.09% compared to the previous year's 10.86 billion. Earnings were 1.05 billion, a decrease of -1.04%.
Financial numbers in GBP Financial StatementsNews
Tombras Acquires New York Agency The Burns Group
Global independent agency Tombras has acquired The Burns Group, an independent advertising agency based in New York. The acquisition further bolsters Tombras' capabilities with top CPG clients, includ...
Pfizer sells further shares in Sensodyne maker Haleon for £2.4bn
Haleon was formed in 2019 by the merger of the consumer healthcare businesses of GSK and US rival Pfizer, but was spun out and floated in 2022.
Pfizer cuts Haleon stake in $3.3B share sale
Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual divestment strategy. Read more here.
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer Inc. (NYSE: PFE) has divested a $3.3 billion stake in Haleon (NYSE: HLN), reducing its holding in the British consumer healthcare company. What Happened : The transaction occurred on Monday, ...
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
Dr Reddy's completes acquisition of UK co Haleon's non-US nicotine replacement therapy biz
Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine replacement therapy (NRT) business for GBP 458 million. The deal includes b...
Pfizer to Pare Back Haleon Stake With 540 Million Share Offering
Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
Sensodyne maker Haleon to raise stake in China JV
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
20 'Every Day Stocks' I'd Struggle To Live Without
In this article, I go through a typical day and note 20 stocks whose revenue I contribute to, and would find it difficult not to. One motivation was to see how much of my budget at attention go into M...
Haleon Announces the Launch of Eroxon®, The First and Only FDA Cleared OTC Gel for Erectile Dysfunction, Available for U.S. Preorder Without a Prescription
Eroxon ® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men with ED Eroxon® is available now for Amazon pre-order; available on shelves an...
Top 2 Risk Off Stocks That May Implode In August
As of Aug 9, 2024, two stocks in the consumer staples sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GB...
Haleon plc (HLN) Q2 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN) Q2 2024 Earnings Call August 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Investor Relations Brian McNamara - Chief Executive Officer Tobias Hestler - Chief Financia...
Haleon sees high single-digit growth for annual organic operating profit
Consumer healthcare firm Haleon on Thursday forecast high single-digit growth for its 2024 organic operating profit, after it posted a 4% rise in half-year pre-tax earnings amid strong demand for its ...
Haleon to sell nicotine replacement therapy business outside US for $633 mln
British consumer healthcare company Haleon said on Wednesday it would sell its nicotine replacement therapy business outside the United States to a unit of India's Dr. Reddy's for 500 million pounds (...
Yellow Wood Partners Portfolio Company Suave Brands Company Completes ChapStick Acquisition
BOSTON , June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its...
GSK raises $1.5 bln from offloading Haleon stake at a discount
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
GSK intends to sell its remaining stake in Haleon
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
Haleon plc (HLN) Q1 2024 Earnings Call Transcript
Haleon plc (NYSE:HLN) Q1 2024 Earnings Conference Call May 1, 2024 4:00 AM ET Company Participants Sonya Ghobrial - Head, Investor Relations Tobias Hestler - Chief Financial Officer Conference Call P...
Haleon's first-quarter revenue misses expectations
Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a s...
Sensodyne-maker Haleon to shut UK manufacturing site, with more than 400 jobs hit
Consumer healthcare company Haleon is planning to shut down its manufacturing site in Britain by 2026, which will impact 435 jobs, a spokesperson told Reuters on Tuesday.
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale
Pfizer is raising around $4.27 billion from the sale of part of its stake in consumer-healthcare business Haleon.
Consumer healthcare giant Haleon says Pfizer to cut stake to 24%
Consumer healthcare giant Haleon said on Monday that Pfizer will sell about 630 million of its shares in the company, reducing the US drugmaker's stake to about 24%.
Haleon CEO: We expect to see volume growth in 2024
Brian McNamara, CEO of Haleon, joins to discuss the firm's earnings. The consumer health company says it expects the operating environment to remain challenging, but is eyeing up to 6% organic revenue...